Generation of a mouse tumor necrosis factor mutant with antiperitonitis and desensitization activities comparable to those of the wild type but with reduced systemic toxicity

Infection and Immunity

Volumn 65, Issue 6, 1997, Pages 2006-2010

  Lucas, R ^a   Echtenacher, B ^b   Sablon, E ^c   Juillard, P ^a   Magez, S ^d   Lou, J ^a   Donati, Y ^a   Bosman, F ^c   Van de Voorde, A ^c   Fransen, L ^c   Mannel D N ^b   Grau, G E ^a   De Baetselier, P ^d  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c INNOGENETICS   (Belgium)

^d FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL INFECTION; BINDING AFFINITY; DESENSITIZATION; DRUG RECEPTOR BINDING; GENE MUTATION; IMMUNOTOXICITY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION;

EID: 0030962992     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.6.2006-2010.1997     Document Type: Article

References (29)

1. Alexander, H. R., B. C. Sheppard, J. C. Jensen, H. N. Langstein, C. M. Buresh, D. Venzon, E. C. Walker, D. L. Fraker, M. C. Stovroff, and J. A. Norton. 1991. Treatment with recombinant human necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram- negative sepsis. J. Clin. Invest. 88:34-39.
2. Beutler, B., I. W. Milsark, and A. C. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871.
3. Brieland, J. K., D. G. Remick, P. T. Freeman, M. C. Hurley, J. C. Fantone, and N. C. Engleberg. 1995. In vivo regulation of replicative Legionella pneumophila lung infection by endogenous tumor necrosis factor alpha and nitric oxide. Infect. Immun. 63:3253-3258.
4. Brouckaert, P., C. Libert, B. Everaerdt, und W. Fiers. 1992. Selective species specificity of tumor necrosis factor for toxicity in the mouse. Lymph. Cytokine Res. 11:193-196.
5. 4a.Echtenacher, B., et al. Unpublished data.
6. Echtenacher, B., W. Falk, D. N. Männel, and P. H. Krammer. 1990. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 145:3762-3766.
7. Erickson, S. L., F. J. Desauvage, K. Kikly, K. Carvermoore, S. Pittsmeek, N. Gillett, K. C. F. Sheehan, R. D. Schreiber, D. V. Goeddel, and M. W. Moore. 1994. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372:560-563.
8. Flynn, J. L., M. M. Goldstein, J. Chan, K. J. Triebold, K. Pfeffer, C. J. Lowenstein, K. Schreiber, T. W. Mak, und B. R. Bloom. 1995. Tumor necrosis factor-alpha is required in the protective immune response against mycobacterium tuberculosis in mice. Immunity 2:561-572.
9. Fransen, L., J. Van der Heyden, R. Ruysschaert, and W. Fiers. 1986. Recombinant tumor necrosis factor: its effect and its synergism with interferon- gamma on a variety of normal and transformed human cell lines. Eur. J. Cancer Clin. Oncol. 22:419-425.
10. Hession, C., J. M. Decker, A. P. Sherblom, S. Kumar, C. C. Yue, R. J. Mattaliano, R. Tizard, E. Kawashima, U. Schmeissner, S. Heletky, E. P. Chow, C. A. Burne, A. Shaw, and A. V. Muchmore. 1987. Uromodulin (Tamm-Horsfall glycoprotein): a renal ligand for lymphokines. Science 237: 1479-1484.
11. Levesque, M. C., A. Paquet, and M. Page. 1995. Improved fluorescent bioassay for the detection of tumor necrosis factor activity. J. Immunol. Methods 178:71-76.
12. Lewis, M., L. A. Tartaglia, A. Lee, G. L. Bennett, G. C. Rice, G. H. W. Wong. E. Y. Chen, and D. V. Goeddel. 1991. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc. Natl. Acad. Sci. USA 88:2830-2834.
13. 11a.Lucas, R., et al. Submitted for publication.
14. Lucas, R., S. Magez, R. De Leys, L. Fransen, J.-P. Scheerlinck, M. Rampel berg, E. Sablon, and P. De Baetselier. 1994. Mapping the lectin-like activity of tumor necrosis factor. Science 263:814-817.
15. McMasters, K. M., J. C. Peyton, D. J. Hadjiminas, and W. G. Cheadle. 1994. Endotoxin and tumour necrosis factor do not cause mortality from cecal ligation and puncture. Cytokine 6:530-536.
16. Pfeffer, K., T. Matsuyama, T. M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P. S. Ohashi, M. Kronke, and T. W. Mak. 1993. Mice deficient for the 55kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457- 467.
17. Ranges, G. E., M. P. Bombara, R. A. Aiyer, G. G. Rice, and M. A. Palladino, Jr. 1989. Tumor necrosis factor-α as a proliferative signal for an IL-2- dependent T cell line: strict species specificity of action. J. Immunol. 142: 1203-1208.
18. Remick, D., P. Manohar, G. Bolgos, J. Rodriguez, L. Moldawer, and G. Wollenberg. 1495. Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 4:89-95.
19. Rothe, J., W. Lesslauer, H. Loetscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor-1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798-802.
20. Steinshamn, S., M. H. A. Bemelmans, L. J. H. van Tits, K. Bergh, W. A. Buurman, and A. Waage. 1996. TNF receptors in murine Candida albicans infection - evidence for an important role of TNF receptor p55 in antifungal defense. J. Immunol. 157:2155-2159.
21. Tacchini-Cottier, F., J.-N. Lou, D. J. Roberts, A. M. Garcia, and G. E. Grau. 1995. Detection of an LFA-1 epitope on the surface of erythrocytes infected with P. falciparum. Immunology 85:205-213.
22. Takahashi, N., P. Brouckaert, and W. Fiers. 1991. Induction of tolerance allows separation of lethal and antitumor activities of tumor necrosis factor in mice. Cancer Res. 51:2366-2372.
23. Takahashi, N., P. Brouckaert, and W. Fiers. 1995. Mechanisms of tolerance to tumor necrosis factor: receptor-specific pathway and selectivity. Am. J. Physiol. 269:398-405.
24. Takeda, K., S. Iwamoto, and M. Takeda. 1994. Lymphotoxin and TNF differ greatly in capacity to induce differentiation of human myeloblastic leukemia ML-1 cells. Biochem. Mol. Biol. Int. 32:1109-1119.
25. Vandenabeele, P., W. Declercq, R. Beyaert, and W. Fiers. 1995. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 5:392- 399.
26. Van Ostade, X., P. Vandenabeele, B. Everaerdt, H. Loetscher, R. Gentz, M. Brockhaus, W. Lesslauer, J. Tavernier, P. Brouckaert, and W. Fiers. 1993. Human TNF mutants with selective activity on the p55 receptor. Nature 361:266-269.
27. Van Zee, K. J., S. A. Stackpole, W. J. Montegut, M. A. Rogy, S. E. Calvano, K. C. Hus, M. Chao, C. L. Meschter, H. Loetscher, D. Stuber, U. Ettlin, B. Wipf, W. Lesslauer, S. F. Lowry, and L. L. Moldawer. 1994. A human tumor necrosis factor (TNF) alpha mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon. J. Exp. Med. 179:1185-1191.
28. Wallach, D., H. Holtmann, H. Engelmann, and Y. Nophar. 1988. Sensitization and desensitization to lethal effects of tumor necrosis and IL-1. J. Immunol. 140:2994-2999.
29. Wichterman, K. A., A. E. Baue, and I. H. Chaudry. 1980. Sepsis and septic shock - a review of laboratory models and a proposal. J. Surg. Res. 29:189- 201.